Tobias Herold

The paper identifies suppressive atypical memory B cells in AML that are amplified by CAR T cell interactions and shows that targeting both B cells and AML blasts can overcome this suppression.

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

The paper develops patient-derived AML PDX models that replicate primary AML biology and include subgroups lacking existing models, showing reduced leukemia growth after long-term chemotherapy.

Pyjacker detects enhancer hijacking in AML, identifying MNX1 activation via 7q deletion as a novel oncogenic mechanism.